Guilford To Receive $40 Mil. To Fund Parkinson's/ED Drug Development Via Investment Deal

Newly formed corporation of investors, Symphony Neuro Development Company, will provide the funds in exchange for five-year warrants to purchase Guilford stock and exclusive rights to the drug. Guilford has an option to reacquire the drug for $75 mil.-$120 mil. between April 2005 and March 2007.